Page last updated: 2024-12-07
3,5,7,3',4'-pentamethoxyflavone
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
3,5,7,3',4'-pentamethoxyflavone: causes relaxation of cavernosum; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 97332 |
| CHEMBL ID | 19032 |
| SCHEMBL ID | 2286327 |
| MeSH ID | M0579747 |
Synonyms (73)
| Synonym |
|---|
| nsc618936 |
| nsc-618936 |
| pentamethylquercetin |
| SDCCGMLS-0066841.P001 |
| smr000386999 |
| MLS001048983 |
| SPECTRUM_001718 |
| SPECTRUM4_001790 |
| SPECTRUM5_000439 |
| BSPBIO_003338 |
| 4h-1-benzopyran-4-one,4-dimethoxyphenyl)-3,5,7-trimethoxy- |
| quercetin pentamethyl ether |
| 3,4',5,7-pentamethoxyflavone |
| flavone,3',4',5,7-pentamethoxy- |
| nsc115922 |
| 1247-97-8 |
| penta-o-methylquercitin |
| nsc-115922 |
| quercetin-3,5,7,3',4'-pentamethylether |
| NCGC00095759-01 |
| KBIO2_004766 |
| KBIOGR_002341 |
| KBIO2_002198 |
| KBIOSS_002198 |
| KBIO2_007334 |
| KBIO3_002558 |
| SPECTRUM3_001719 |
| SPECTRUM2_001804 |
| SPBIO_001787 |
| SPECTRUM1600075 |
| NCGC00178132-01 |
| pentamethoxyquercetin |
| CHEMBL19032 , |
| 2-(3,4-dimethoxyphenyl)-3,5,7-trimethoxychromen-4-one |
| LMPK12112772 |
| NCGC00095759-02 |
| flavone, 3,3',4',5,7-pentamethoxy- |
| 4h-1-benzopyran-4-one, 2-(3,4-dimethoxyphenyl)-3,5,7-trimethoxy- |
| v6j41k636o , |
| quercetin-3,5,7,3',4'-pentamethyl ether |
| nsc 115922 |
| unii-v6j41k636o |
| 3,5,7,3',4'-pentamethyl ether |
| 3,3',4',5,7-pentamethoxyflavone |
| HMS2268P21 |
| CCG-38450 |
| bdbm50404748 |
| AB00637125-07 |
| mfcd01004607 |
| SCHEMBL2286327 |
| 2-(3,4-dimethoxyphenyl)-3,5,7-trimethoxy-chromen-4-one |
| quercetin 3, 5, 7, 3', 4'-pentamethylether |
| ALGDHWVALRSLBT-UHFFFAOYSA-N |
| 3,5,7,3',4'-pentamethoxyflavone |
| quercetin 3,5,7,3',4'-pentamethyl ether |
| DTXSID10154467 |
| 4h-1-benzopyran-4-one,2-(3,4-dimethoxyphenyl)-3,5,7-trimethoxy- |
| AKOS030487720 |
| SR-01000758970-2 |
| sr-01000758970 |
| 2-(3,4-dimethoxyphenyl)-3,5,7-trimethoxy-4h-1-benzopyran-4-one |
| 2-(3,4-dimethoxyphenyl)-3,5,7-trimethoxy-4h-chromen-4-one |
| STL512455 |
| tum-8437 |
| FT-0716793 |
| MS-26004 |
| quercetin 3,5,7,3,4-pentamethyl ether |
| 3,5,7,3 inverted exclamation marka,4 inverted exclamation marka-pentamethoxyflavone |
| quercetin-3,5,7,3,4-pentamethylether |
| 3,3`,4`,5,7-pentamethoxyflavone |
| E80655 |
| CS-0135217 |
| HY-N7690 |
Research Excerpts
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " Male rats were orally or intravenously administered a 250 mg/kg concentration of a KP extract, and blood samples were obtained at selected times to determine pharmacokinetic parameters of PMF, TMF, and DMF." | ( Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats. Jay, M; Mekjaruskul, C; Sripanidkulchai, B, 2012) | 0.38 |
| " Additional blood samples were collected at various times on the last day of treatment to evaluate the pharmacokinetic interactions." | ( Pharmacokinetic interaction between Kaempferia parviflora extract and sildenafil in rats. Mekjaruskul, C; Sripanidkulchai, B, 2015) | 0.42 |
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| " The methoxyflavones showed low oral bioavailability of 1 to 4%." | ( Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats. Jay, M; Mekjaruskul, C; Sripanidkulchai, B, 2012) | 0.38 |
| " However, quercetin's low solubility and poor bioavailability have restricted its applicability; as a result, researchers have attempted to design and synthesize numerous novel quercetin derivatives using various methodologies in order to modify quercetin's constraints; the physico-chemical properties of quercetin's molecular scaffold make it appealing for drug development; low molecular mass and chemical groups are two of these characteristics." | ( Quercetin derivatives: Drug design, development, and biological activities, a review. Alizadeh, SR; Ebrahimzadeh, MA, 2022) | 0.72 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (38)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 10.0000 | 0.0040 | 23.8416 | 100.0000 | AID485290 |
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 39.8107 | 0.0447 | 17.8581 | 100.0000 | AID485341 |
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 33.5521 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
| Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 50.1187 | 5.6234 | 17.2929 | 31.6228 | AID485281 |
| acid sphingomyelinase | Homo sapiens (human) | Potency | 25.1189 | 14.1254 | 24.0613 | 39.8107 | AID504937 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 12.5893 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 56.2341 | 0.1000 | 20.8793 | 79.4328 | AID588456 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 7.3048 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
| TDP1 protein | Homo sapiens (human) | Potency | 20.7329 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 19.9526 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| mitogen-activated protein kinase 1 | Homo sapiens (human) | Potency | 20.4053 | 0.0398 | 16.7842 | 39.8107 | AID1454; AID995 |
| flap endonuclease 1 | Homo sapiens (human) | Potency | 79.4328 | 0.1337 | 25.4129 | 89.1251 | AID588795 |
| peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Potency | 44.6684 | 0.4256 | 12.0591 | 28.1838 | AID504891 |
| cytochrome P450 3A4 isoform 1 | Homo sapiens (human) | Potency | 1.2589 | 0.0316 | 10.2792 | 39.8107 | AID884; AID885 |
| muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 25.1189 | 0.0041 | 9.9625 | 28.1838 | AID2675 |
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Potency | 1.2589 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Potency | 1.2589 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Potency | 1.2589 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Potency | 1.2589 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Potency | 1.2589 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Potency | 1.2589 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Potency | 1.2589 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Potency | 1.2589 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 1.2589 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Potency | 1.2589 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Potency | 1.2589 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Potency | 1.2589 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Potency | 1.2589 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 1.2589 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | Potency | 1.2589 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Potency | 1.2589 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | IC50 (µMol) | 23.4000 | 0.0002 | 2.3185 | 10.0000 | AID768684 |
| Multidrug resistance-associated protein 1 | Homo sapiens (human) | IC50 (µMol) | 26.3500 | 0.0015 | 3.7110 | 9.6600 | AID768683 |
| Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B | Rattus norvegicus (Norway rat) | IC50 (µMol) | 1,000.0000 | 0.1000 | 0.2000 | 0.3000 | AID220159 |
| Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C | Rattus norvegicus (Norway rat) | IC50 (µMol) | 1,000.0000 | 0.1000 | 0.2000 | 0.3000 | AID220159 |
| Phosphodiesterase | Rattus norvegicus (Norway rat) | IC50 (µMol) | 1,000.0000 | 0.1000 | 0.2000 | 0.3000 | AID220159 |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | IC50 (µMol) | 1.3510 | 0.0040 | 1.9666 | 10.0000 | AID768689; AID768691 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (39)
Molecular Functions (27)
Ceullar Components (14)
Bioassays (121)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1223522 | Cmax in Wistar rat brain at 750 mg/kg, po by LC-MS/MS analysis | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12 | Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats. |
| AID596470 | Effect on C/EBPbeta mRNA expression in mouse 3T3L1 cells at 10 uM on day 8 by RT-PCR relative to beta-actin mRNA expression | 2011 | Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9 | Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells. |
| AID596452 | Induction of insulin-stimulated 2-deoxy-D- 2,6-[3H]-glucose uptake in differentiated mouse 3T3L1 cells at 30 uM compound treated for 20 mins with insulin by liquid scintillation counting (Rvb = 100.0 %) | 2011 | Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9 | Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells. |
| AID220005 | Relative inhibition of cAMP and cGMP hydrolysis by cytosolic phosphodiesterase | 1982 | Journal of medicinal chemistry, Oct, Volume: 25, Issue:10 | Pentasubstituted quercetin analogues as selective inhibitors of particulate 3':5'-cyclic-AMP phosphodiesterase from rat brain. |
| AID666771 | Inhibition of thrombin in New Zealand rabbit plasma assessed as fibrinogen level at 100 uM by coagulometry | 2012 | European journal of medicinal chemistry, Aug, Volume: 54 | Metabolism-based synthesis, biologic evaluation and SARs analysis of O-methylated analogs of quercetin as thrombin inhibitors. |
| AID596454 | Effect on adiponectin mRNA expression in mouse 3T3L1 cells at 3 uM on day 8 by RT-PCR relative to beta-actin mRNA expression | 2011 | Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9 | Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells. |
| AID596677 | Induction of adiponectin protein secretion in mouse 3T3L1 cells at 30 uM on day 8 by ELISA relative to control | 2011 | Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9 | Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells. |
| AID596455 | Effect on adiponectin mRNA expression in mouse 3T3L1 cells at 30 uM on day 8 by RT-PCR relative to beta-actin mRNA expression | 2011 | Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9 | Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells. |
| AID596449 | Induction of insulin-stimulated 2-deoxy-D- 2,6-[3H]-glucose uptake in mouse 3T3L1 cells chronically treated at 30 uM by liquid scintillation counting (Rvb = 100.0 %) | 2011 | Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9 | Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells. |
| AID1223521 | Cmax in Wistar rat lung at 750 mg/kg, po by LC-MS/MS analysis | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12 | Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats. |
| AID596457 | Effect on PPARgamma2 mRNA expression in mouse 3T3L1 cells at 3 uM on day 8 by RT-PCR relative to beta-actin mRNA expression | 2011 | Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9 | Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells. |
| AID596671 | Induction of adipogenesis in mouse 3T3L1 cells assessed as increase in triglyceride level at 3 uM on day 8 relative to control | 2011 | Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9 | Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells. |
| AID1223558 | Elimination rate constant in Wistar rat at 250 mg/kg, po by HPLC analysis | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12 | Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats. |
| AID1705065 | Inhibition of biotinylated 5-(4-((Z)-3-Carboxy-3-hydroxyacryloyl)-4-(4-chlorobenzyl)piperidine-1-carbonyl)-2-((13,35-dioxo-39-((3aR,4R,6aS)-2-oxohexahydro-1H-thieno[3,4-d]imidazole-4-yl)-3,6,9,16,19,22,25,28,31-nonaoxa-12,34-diazanonatriacontyl)oxy)benzoi | 2020 | European journal of medicinal chemistry, Dec-15, Volume: 208 | Unraveling the anti-influenza effect of flavonoids: Experimental validation of luteolin and its congeners as potent influenza endonuclease inhibitors. |
| AID596464 | Effect on aP2 mRNA expression in mouse 3T3L1 cells at 10 uM on day 8 by RT-PCR relative to beta-actin mRNA expression | 2011 | Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9 | Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells. |
| AID596469 | Effect on C/EBPbeta mRNA expression in mouse 3T3L1 cells at 3 uM on day 8 by RT-PCR relative to beta-actin mRNA expression | 2011 | Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9 | Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells. |
| AID1223564 | Volume of distribution in Wistar rat at 250 mg/kg, po by HPLC analysis | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12 | Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats. |
| AID768691 | Inhibition of human BCRP expressed in MDCK2 cells assessed as accumulation of Hoechst 33342 preincubated for 30 mins before Hoechst 33342 addition measured after 120 mins by fluorescence assay | 2013 | European journal of medicinal chemistry, Sep, Volume: 67 | Synthesis and biological evaluation of flavones and benzoflavones as inhibitors of BCRP/ABCG2. |
| AID1223549 | Drug metabolism in Wistar rat assessed as excretion of 5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-3,7-dimethoxy-4H-chromen-4-one in urine/feces at 750 mg/kg, po by LC-MS and LC-MS/MS analysis | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12 | Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats. |
| AID220001 | Inhibition of rat brain cytosolic cAMP phosphodiesterase | 1982 | Journal of medicinal chemistry, Oct, Volume: 25, Issue:10 | Pentasubstituted quercetin analogues as selective inhibitors of particulate 3':5'-cyclic-AMP phosphodiesterase from rat brain. |
| AID220162 | Inhibition of rat brain particulate cGMP phosphodiesterase | 1982 | Journal of medicinal chemistry, Oct, Volume: 25, Issue:10 | Pentasubstituted quercetin analogues as selective inhibitors of particulate 3':5'-cyclic-AMP phosphodiesterase from rat brain. |
| AID1223556 | Half life in Wistar rat at 250 mg/kg, po by HPLC analysis | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12 | Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats. |
| AID1223534 | Drug metabolism in Wistar rat assessed as excretion of 3,5-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-methoxy-4H-chromen-4-one in feces at 750 mg/kg, po by LC-MS and LC-MS/MS analysis | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12 | Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats. |
| AID1223565 | Absorption rate constant in Wistar rat at 250 mg/kg, po by HPLC analysis | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12 | Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats. |
| AID596669 | Induction of adipogenesis in mouse 3T3L1 cells assessed as increase in triglyceride level at 0.3 uM on day 8 relative to control | 2011 | Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9 | Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells. |
| AID596247 | Effect on C/EBPdelta mRNA expression in mouse 3T3L1 adipocytes at 30 uM on day 8 by RT-PCR relative to beta-actin mRNA expression | 2011 | Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9 | Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells. |
| AID596673 | Induction of adipogenesis in mouse 3T3L1 cells assessed as increase in triglyceride level at 30 uM on day 8 relative to control | 2011 | Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9 | Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells. |
| AID596466 | Effect on C/EBPalpha mRNA expression in mouse 3T3L1 cells at 3 uM on day 8 by RT-PCR relative to beta-actin mRNA expression | 2011 | Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9 | Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells. |
| AID596468 | Effect on C/EBPalpha mRNA expression in mouse 3T3L1 cells at 30 uM on day 8 by RT-PCR relative to beta-actin mRNA expression | 2011 | Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9 | Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells. |
| AID596246 | Effect on C/EBPdelta mRNA expression in mouse 3T3L1 cells at 10 uM on day 8 by RT-PCR relative to beta-actin mRNA expression | 2011 | Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9 | Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells. |
| AID596672 | Induction of adipogenesis in mouse 3T3L1 cells assessed as increase in triglyceride level at 10 uM on day 8 relative to control | 2011 | Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9 | Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells. |
| AID1223561 | Clearance in Wistar rat at 250 mg/kg, iv by HPLC analysis | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12 | Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats. |
| AID1677633 | Activation of CRE-mediated transcription in rat PC12D cells transfected with pCRE-firefly luciferase and pRL-null-renilla luciferase assessed as increase in CRE-driven firefly luciferase activity at 30 uM by dual luciferase reporter gene assay | 2020 | Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23 | Effect of methoxyflavones contained in Kaempferia parviflora on CRE-mediated transcription in PC12D cells. |
| AID768685 | Inhibition of MRP1 (unknown origin) expressed in human 2008 cells assessed as calcein-AM accumulation at 10 uM preincubated for 30 mins before calcein-AM addition measured up to 90 mins by fluorescence assay relative to control | 2013 | European journal of medicinal chemistry, Sep, Volume: 67 | Synthesis and biological evaluation of flavones and benzoflavones as inhibitors of BCRP/ABCG2. |
| AID1223557 | Half life in Wistar rat at 250 mg/kg, iv by HPLC analysis | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12 | Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats. |
| AID1223560 | Clearance in Wistar rat at 250 mg/kg, po by HPLC analysis | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12 | Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats. |
| AID596679 | Induction of insulin-stimulated 2-deoxy-D- 2,6-[3H]-glucose uptake in mouse 3T3L1 cells chronically treated at 3 uM by liquid scintillation counting (Rvb = 100.0 %) | 2011 | Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9 | Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells. |
| AID596676 | Induction of adiponectin protein secretion in mouse 3T3L1 cells at 10 uM on day 8 by ELISA relative to control | 2011 | Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9 | Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells. |
| AID1223567 | AUC (0.083 to 4 hrs) in Wistar rat liver at 750 mg/kg, po by LC-MS/MS analysis | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12 | Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats. |
| AID596462 | Effect on GlUT4 mRNA expression in mouse 3T3L1 cells at 30 uM on day 8 by RT-PCR relative to beta-actin mRNA expression | 2011 | Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9 | Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells. |
| AID1223527 | Tmax in Wistar rat brain at 750 mg/kg, po by LC-MS/MS analysis | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12 | Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats. |
| AID1223519 | Cmax in Wistar rat liver at 750 mg/kg, po by LC-MS/MS analysis | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12 | Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats. |
| AID1223563 | Cmax in Wistar rat at 250 mg/kg, po by HPLC analysis | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12 | Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats. |
| AID768683 | Inhibition of MRP1 (unknown origin) expressed in human 2008 cells assessed as calcein-AM accumulation preincubated for 30 mins before calcein-AM addition measured up to 90 mins by fluorescence assay | 2013 | European journal of medicinal chemistry, Sep, Volume: 67 | Synthesis and biological evaluation of flavones and benzoflavones as inhibitors of BCRP/ABCG2. |
| AID1223547 | Drug excretion in Wistar rat feces at 750 mg/kg, po after 18 to 24 hrs by HPLC-UV analysis | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12 | Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats. |
| AID1677634 | Effect on transcription in rat PC12D cells transfected with pCRE-firefly luciferase and pRL-null-renilla luciferase assessed as renilla luciferase activity at 30 uM by dual luciferase reporter gene assay | 2020 | Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23 | Effect of methoxyflavones contained in Kaempferia parviflora on CRE-mediated transcription in PC12D cells. |
| AID596467 | Effect on C/EBPalpha mRNA expression in mouse 3T3L1 cells at 10 uM on day 8 by RT-PCR relative to beta-actin mRNA expression | 2011 | Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9 | Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells. |
| AID666857 | Reversal of BCRP-mediated drug resistant in human HEK293/R2 cells assessed as potentiation of topotecan-induced cytotoxicity at 1 uM after 5 days by MTS assay | 2012 | European journal of medicinal chemistry, Aug, Volume: 54 | Synthesis of methylated quercetin derivatives and their reversal activities on P-gp- and BCRP-mediated multidrug resistance tumour cells. |
| AID1223524 | Tmax in Wistar rat liver at 750 mg/kg, po by LC-MS/MS analysis | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12 | Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats. |
| AID666855 | Cytotoxicity against mouse L929 cells after 5 days by MTS assay | 2012 | European journal of medicinal chemistry, Aug, Volume: 54 | Synthesis of methylated quercetin derivatives and their reversal activities on P-gp- and BCRP-mediated multidrug resistance tumour cells. |
| AID596670 | Induction of adipogenesis in mouse 3T3L1 cells assessed as increase in triglyceride level at 1 uM on day 8 relative to control | 2011 | Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9 | Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells. |
| AID1223555 | AUC in Wistar rat at 250 mg/kg, iv by HPLC analysis | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12 | Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats. |
| AID1223559 | Elimination rate constant in Wistar rat at 250 mg/kg, iv by HPLC analysis | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12 | Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats. |
| AID1871969 | Antioxidant activity assessed as DPPH radical scavenging activity after 30 mins under dark condition | 2022 | European journal of medicinal chemistry, Feb-05, Volume: 229 | Quercetin derivatives: Drug design, development, and biological activities, a review. |
| AID219998 | Inhibition of rat brain cytosolic cAMP phosphodiesterase | 1982 | Journal of medicinal chemistry, Oct, Volume: 25, Issue:10 | Pentasubstituted quercetin analogues as selective inhibitors of particulate 3':5'-cyclic-AMP phosphodiesterase from rat brain. |
| AID220159 | Inhibition of rat brain cytosolic cGMP phosphodiesterase | 1982 | Journal of medicinal chemistry, Oct, Volume: 25, Issue:10 | Pentasubstituted quercetin analogues as selective inhibitors of particulate 3':5'-cyclic-AMP phosphodiesterase from rat brain. |
| AID666768 | Inhibition of thrombin in New Zealand rabbit plasma assessed as thrombin time at 100 uM after 3 mins by coagulometry | 2012 | European journal of medicinal chemistry, Aug, Volume: 54 | Metabolism-based synthesis, biologic evaluation and SARs analysis of O-methylated analogs of quercetin as thrombin inhibitors. |
| AID596451 | Induction of insulin-stimulated 2-deoxy-D- 2,6-[3H]-glucose uptake in differentiated mouse 3T3L1 cells at 10 uM compound treated for 20 mins with insulin by liquid scintillation counting (Rvb = 100.0 %) | 2011 | Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9 | Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells. |
| AID596667 | Induction of adipogenesis in mouse 3T3L1 cells assessed as increase in triglyceride level on day 8 | 2011 | Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9 | Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells. |
| AID1223530 | Drug excretion in Wistar rat urine at 750 mg/kg, po after 12 hrs by HPLC-UV analysis | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12 | Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats. |
| AID1223554 | AUC in Wistar rat at 250 mg/kg, po by HPLC analysis | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12 | Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats. |
| AID596450 | Induction of insulin-stimulated 2-deoxy-D- 2,6-[3H]-glucose uptake in differentiated mouse 3T3L1 cells at 3 uM compound treated for 20 mins with insulin by liquid scintillation counting (Rvb = 100.0 %) | 2011 | Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9 | Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells. |
| AID596674 | Induction of adiponectin protein secretion in mouse 3T3L1 cells at 1 uM on day 8 by ELISA relative to control | 2011 | Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9 | Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells. |
| AID1223566 | Oral bioavailability in Wistar rat at 250 mg/kg by HPLC analysis | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12 | Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats. |
| AID1223536 | Drug excretion in Wistar rat feces at 750 mg/kg, po after up to 72 hrs by HPLC-UV analysis | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12 | Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats. |
| AID666770 | Inhibition of thrombin in New Zealand rabbit plasma assessed as activated partial thromboplastin time at 100 uM after 3 mins by coagulometry | 2012 | European journal of medicinal chemistry, Aug, Volume: 54 | Metabolism-based synthesis, biologic evaluation and SARs analysis of O-methylated analogs of quercetin as thrombin inhibitors. |
| AID1223535 | Drug excretion in Wistar rat urine at 750 mg/kg, po after up to 72 hrs by HPLC-UV analysis | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12 | Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats. |
| AID1223570 | AUC (0.083 to 4 hrs) in Wistar rat brain at 750 mg/kg, po by LC-MS/MS analysis | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12 | Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats. |
| AID1677632 | Cytotoxicity against rat PC12D cells assessed as reduction in cell viability at 30 uM by MTT assay | 2020 | Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23 | Effect of methoxyflavones contained in Kaempferia parviflora on CRE-mediated transcription in PC12D cells. |
| AID1223545 | Drug excretion in Wistar rat urine at 750 mg/kg, po after 24 to 72 hrs by HPLC-UV analysis | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12 | Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats. |
| AID666853 | Cytotoxicity against human LCC-6 cells after 5 days by MTS assay | 2012 | European journal of medicinal chemistry, Aug, Volume: 54 | Synthesis of methylated quercetin derivatives and their reversal activities on P-gp- and BCRP-mediated multidrug resistance tumour cells. |
| AID1223569 | AUC (0.083 to 4 hrs) in Wistar rat lung at 750 mg/kg, po by LC-MS/MS analysis | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12 | Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats. |
| AID768689 | Inhibition of human BCRP expressed in MDCK2 cells assessed as accumulation of pheophorbide-A preincubated for 30 mins before pheophorbide-A addition measured after 120 mins by flow cytometry | 2013 | European journal of medicinal chemistry, Sep, Volume: 67 | Synthesis and biological evaluation of flavones and benzoflavones as inhibitors of BCRP/ABCG2. |
| AID596245 | Effect on C/EBPdelta mRNA expression in mouse 3T3L1 cells at 3 uM on day 8 by RT-PCR relative to beta-actin mRNA expression | 2011 | Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9 | Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells. |
| AID666769 | Inhibition of thrombin in New Zealand rabbit plasma assessed as prothrombin time at 100 uM by coagulometry | 2012 | European journal of medicinal chemistry, Aug, Volume: 54 | Metabolism-based synthesis, biologic evaluation and SARs analysis of O-methylated analogs of quercetin as thrombin inhibitors. |
| AID1223526 | Tmax in Wistar rat lung at 750 mg/kg, po by LC-MS/MS analysis | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12 | Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats. |
| AID1223531 | Drug excretion in Wistar rat feces at 750 mg/kg, po after 12 hrs by HPLC-UV analysis | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12 | Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats. |
| AID596448 | Induction of insulin-stimulated 2-deoxy-D- 2,6-[3H]-glucose uptake in mouse 3T3L1 cells chronically treated at 10 uM by liquid scintillation counting (Rvb = 100.0 %) | 2011 | Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9 | Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells. |
| AID596460 | Effect on GlUT4 mRNA expression in mouse 3T3L1 cells at 3 uM on day 8 by RT-PCR relative to beta-actin mRNA expression | 2011 | Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9 | Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells. |
| AID1223562 | Tmax in Wistar rat at 250 mg/kg, po by HPLC analysis | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12 | Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats. |
| AID1223568 | AUC (0.083 to 4 hrs) in Wistar rat kidney at 750 mg/kg, po by LC-MS/MS analysis | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12 | Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats. |
| AID1223528 | Tmax in Wistar rat testes at 750 mg/kg, po by LC-MS/MS analysis | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12 | Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats. |
| AID1223542 | Drug metabolism in Wistar rat assessed as excretion of 2-(3-hydroxy-4-methoxyphenyl)-3,5,7-trimethoxy-4H-chromen-4-one in urine at 750 mg/kg, po by LC-MS and LC-MS/MS analysis | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12 | Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats. |
| AID596471 | Effect on C/EBPbeta mRNA expression in mouse 3T3L1 cells at 30 uM on day 8 by RT-PCR relative to beta-actin mRNA expression | 2011 | Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9 | Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells. |
| AID596463 | Effect on aP2 mRNA expression in mouse 3T3L1 cells at 3 uM on day 8 by RT-PCR relative to beta-actin mRNA expression | 2011 | Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9 | Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells. |
| AID666858 | Reversal of BCRP-mediated drug resistant in human MCF7-MX100 cells assessed as potentiation of topotecan-induced cytotoxicity at 1 uM after 5 days by MTS assay | 2012 | European journal of medicinal chemistry, Aug, Volume: 54 | Synthesis of methylated quercetin derivatives and their reversal activities on P-gp- and BCRP-mediated multidrug resistance tumour cells. |
| AID596461 | Effect on GlUT4 mRNA expression in mouse 3T3L1 cells at 10 uM on day 8 by RT-PCR relative to beta-actin mRNA expression | 2011 | Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9 | Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells. |
| AID1871970 | Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay relative to control | 2022 | European journal of medicinal chemistry, Feb-05, Volume: 229 | Quercetin derivatives: Drug design, development, and biological activities, a review. |
| AID596678 | Induction of insulin-stimulated 2-deoxy-D- 2,6-[3H]-glucose uptake in mouse 3T3L1 cells chronically treated at 1 uM by liquid scintillation counting (Rvb = 100.0 %) | 2011 | Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9 | Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells. |
| AID596675 | Induction of adiponectin protein secretion in mouse 3T3L1 cells at 3 uM on day 8 by ELISA relative to control | 2011 | Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9 | Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells. |
| AID220006 | Relative inhibition of cAMP and cGMP hydrolysis by particulate phosphodiesterase | 1982 | Journal of medicinal chemistry, Oct, Volume: 25, Issue:10 | Pentasubstituted quercetin analogues as selective inhibitors of particulate 3':5'-cyclic-AMP phosphodiesterase from rat brain. |
| AID666859 | Reversal of MRP1-mediated drug resistant in human 2008/MRP1 cells assessed as potentiation of doxorubicin-induced cytotoxicity at 1 uM after 5 days by MTS assay | 2012 | European journal of medicinal chemistry, Aug, Volume: 54 | Synthesis of methylated quercetin derivatives and their reversal activities on P-gp- and BCRP-mediated multidrug resistance tumour cells. |
| AID1223523 | Cmax in Wistar rat testes at 750 mg/kg, po by LC-MS/MS analysis | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12 | Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats. |
| AID768684 | Inhibition of p-glycoprotein (unknown origin) expressed in human A2780Adr cells assessed as calcein-AM accumulation preincubated for 30 mins before calcein-AM addition measured up to 90 mins by fluorescence assay | 2013 | European journal of medicinal chemistry, Sep, Volume: 67 | Synthesis and biological evaluation of flavones and benzoflavones as inhibitors of BCRP/ABCG2. |
| AID666856 | Reversal of p-glycoprotein-mediated drug resistant in human LCC-6/MDR cells assessed as potentiation of paclitaxel-induced cytotoxicity at 1 uM after 5 days by MTS assay | 2012 | European journal of medicinal chemistry, Aug, Volume: 54 | Synthesis of methylated quercetin derivatives and their reversal activities on P-gp- and BCRP-mediated multidrug resistance tumour cells. |
| AID768686 | Inhibition of p-glycoprotein (unknown origin) expressed in human A2780Adr cells assessed as calcein-AM accumulation at 10 uM preincubated for 30 mins before calcein-AM addition measured up to 90 mins by fluorescence assay relative to control | 2013 | European journal of medicinal chemistry, Sep, Volume: 67 | Synthesis and biological evaluation of flavones and benzoflavones as inhibitors of BCRP/ABCG2. |
| AID404008 | Cytotoxicity against human KB cells | |||
| AID1223538 | AUC (0.083 to 4 hrs) in Wistar rat testes at 750 mg/kg, po by LC-MS/MS analysis | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12 | Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats. |
| AID596459 | Effect on PPARgamma2 mRNA expression in mouse 3T3L1 cells at 30 uM on day 8 by RT-PCR relative to beta-actin mRNA expression | 2011 | Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9 | Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells. |
| AID596456 | Effect on adiponectin mRNA expression in mouse 3T3L1 cells at 10 uM on day 8 by RT-PCR relative to beta-actin mRNA expression | 2011 | Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9 | Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells. |
| AID596458 | Effect on PPARgamma2 mRNA expression in mouse 3T3L1 cells at 10 uM on day 8 by RT-PCR relative to beta-actin mRNA expression | 2011 | Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9 | Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells. |
| AID666854 | Cytotoxicity against multidrug resistant human LCC-6 cells after 5 days by MTS assay | 2012 | European journal of medicinal chemistry, Aug, Volume: 54 | Synthesis of methylated quercetin derivatives and their reversal activities on P-gp- and BCRP-mediated multidrug resistance tumour cells. |
| AID1871971 | Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay | 2022 | European journal of medicinal chemistry, Feb-05, Volume: 229 | Quercetin derivatives: Drug design, development, and biological activities, a review. |
| AID1223520 | Cmax in Wistar rat kidney at 750 mg/kg, po by LC-MS/MS analysis | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12 | Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats. |
| AID596465 | Effect on aP2 mRNA expression in mouse 3T3L1 cells at 30 uM on day 8 by RT-PCR relative to beta-actin mRNA expression | 2011 | Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9 | Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells. |
| AID1223525 | Tmax in Wistar rat kidney at 750 mg/kg, po by LC-MS/MS analysis | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12 | Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| AID1159550 | Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening | 2015 | Nature cell biology, Nov, Volume: 17, Issue:11 | 6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (21)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (4.76) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (4.76) | 29.6817 |
| 2010's | 15 (71.43) | 24.3611 |
| 2020's | 4 (19.05) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 11.77
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.77) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 2 (9.09%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 20 (90.91%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||